Grifols マネジメント

マネジメント基準チェック /24

Grifolsの CEO はNacho Abia Buenacheで、 Apr2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.014%を直接所有しており、その価値は€ 942.54K 。経営陣と取締役会の平均在任期間はそれぞれ6.8年と7年です。

主要情報

Nacho Abia Buenache

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.01%
経営陣の平均在職期間	6.8yrs
取締役会の平均在任期間	7yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Nacho Abia Buenache (56 yo)

less than a year

在職期間

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jose Ignacio Abia Buenache	CEO & Director	less than a year	データなし	0.014% € 942.5k
Alfredo Guerra	CFO & VP	17.8yrs	データなし	データなし
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	データなし	データなし
Nuria Lapeña	VP of Corporate Treasury	no data	データなし	データなし
David Bell	Chief Corporate Development	21.8yrs	データなし	0.0029% € 202.9k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.8yrs	データなし	0.00078% € 53.8k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	データなし	データなし
Vicente Blanquer Torre	Chief Quality Officer	31.8yrs	データなし	データなし
Sergio Adell	President of Commercial Tech Support	5.8yrs	データなし	データなし
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.016% € 1.1m
Miguel Montblanch	President of Commercial Operations Support	12.8yrs	データなし	データなし
Daniel Coit	Chief Industrial Services Officer	5.8yrs	データなし	データなし

6.8yrs

平均在職期間

57.5yo

平均年齢

経験豊富な経営陣: OZTAの経営陣は経験豊富で経験豊富です（平均在職期間は6.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Jose Ignacio Abia Buenache	CEO & Director	less than a year	データなし	0.014% € 942.5k
Víctor Grifols Deu	Executive Director	8.5yrs	€1.04m	0.016% € 1.1m
Iñigo Mardones	Independent Director	9.5yrs	€150.00k	データなし
Thomas Glanzmann	Non-Executive Chairman	18.6yrs	€1.90m	0.029% € 2.0m
Juan Twose Roura	Member of the Advisory Committee	9.8yrs	€380.00k	データなし
Raimon Grifols Roura	Vice-Chairman	9.5yrs	€1.04m	0.0060% € 417.4k
Tomas Daga Gelabert	Independent External Director	24.6yrs	データなし	0.045% € 3.1m
Albert Coma-Cros	Proprietary Director	less than a year	データなし	0.0097% € 670.0k
Enriqueta Font	Independent Director	5.5yrs	€125.00k	データなし
Montserrat Abellana	Lead Independent Director	2.4yrs	€63.00k	データなし
Susana Gonzalez Rodriguez	Independent Director	2.4yrs	€63.00k	データなし
Anne-Catherine Berner	Independent Director	less than a year	データなし	データなし

7.0yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: OZTAの取締役会は経験豊富であると考えられます ( 7年の平均在任期間)。

Grifols マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Recent updates

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Third quarter 2024 earnings released

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: €0.02 (vs €0.06 in 2Q 2023)

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Investor sentiment improves as stock rises 22%

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

New minor risk - Earnings quality

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

First quarter 2024 earnings released

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 45%

Full year 2023 earnings released

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Third quarter 2023 earnings released

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

New major risk - Financial position

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24